Refine by
Ldct Suppliers & Manufacturers
4 companies found
based inMenlo Park, CALIFORNIA (USA)
We are a healthcare company focused on saving lives and improving health by pioneering new technologies for early cancer detection. We have built a multi-disciplinary organization of scientists, engineers, and physicians and we are using the power ...
Evaluation of a New Blood Test for Detecting Multiple Types of Cancer Early. The SUMMIT Study is a prospective, observational, longitudinal, cohort study being conducted in London in the United Kingdom. It is designed to enroll approximately 25,000 ...
based inRichmond, BRITISH COLUMBIA (CANADA)
BioMark is an oncology-focused company with advanced near-to- market liquid biopsy diagnostic technologies. Our technology improves patient comfort, outcomes and early cancer detection. Biomark owns various intellectual properties, developed for the ...
BioMark has invested in and developed a new high powered liquid biopsy metabolic panel assay. The new metabolic assay is instrumental for early stage diagnosis of lung ...
based inValladolid, SPAIN
Founded in 2010, AMADIX is a leading molecular diagnostics company, focused on liquid biopsy, developing innovative diagnostic tests for early cancer detection in blood. Our mission is to extend people’s lives by developing disruptive technologies ...
It can also be used as a tool for a high-risk screening population in combination with Low Dose Computed Tomography (LDCT). DiagnoLung identifies and measures proteins which are differentially expressed in blood samples of ...
based inBuffalo, MINNESOTA (USA)
PenRad offers a total solution for breast imaging and Low Dose Computed Tomography (LDCT) lung screening, enhancing practice workflow. Designed for flexible and for easy integration, PenRad’s client/server SQL enterprise architecture supports all ...
PenRad’s PenGen system allows facilities to collect and manage patients’ risk assessments and genetic testing eligibility. System calculates real-time cancer risk scores, and Genetic testing eligibility based on multiple models, for ...